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Abstract
Background: The gamma-isoform of the 14-3-3 protein (14-3-3 gamma) is expressed in neurons, and could be a
specific marker for neuronal damage. This protein has been reported as a detectable biomarker, especially in the
cerebrospinal fluid (CSF) of Creutzfeldt-Jakob disease (CJD) patients by Western blotting (WB) or enzyme-linked
immunosorbent assays (ELISAs). Western blotting for 14-3-3 gamma is not sensitive, and the reported data are
conflicting among publications. An ELISA specific for 14-3-3 gamma is not available.
Methods: CJD patients (n = 114 sporadic CJD patients, 7 genetic CJD, and 3 iatrogenic CJD) and 99 patients with
other neurodegenerative diseases were examined in this study. The CSF samples obtained were analyzed by
Western blotting for 14-3-3 gamma, and by ELISA for total tau protein. We evaluated the sensitivity and specificity
of the newly developed sandwich ELISA for 14-3-3 gamma.
Results: The cut-off value of the 14-3-3 gamma ELISA was > 1, 683 AU/ml; and sensitivity was 95.2%, with 72.7%
specificity. This specificity was the same for the total tau protein ELISA. Seven CJD cases were negative by WB but
positive using the 14-3-3 gamma ELISA, indicating that the ELISA is more sensitive. All 21 cases of early stage CJD
could be diagnosed using a combination of the 14-3-3g ELISA and diffusion weighted MR imaging (DWI-MRI).
Conclusion: The 14-3-3 gamma ELISA was more sensitive than conventional WB, and was useful for laboratory
diagnosis of CJD, similar to the ELISA for the tau protein. Using DWI-MRI and these ELISA tests on CSF, diagnosis of
CJD will be possible even at early stages of the disease.
Keywords: CJD, CSF, ELISA, prion disease, 14-3-3 protein, tau protein
Background
Hshich et al.[1] reported use of the 14-3-3 protein for
diagnosis of prion diseases in 1996. This protein is a
reliable marker of rapid neuronal destruction, and has
been detected in the cerebrospinal fluid (CSF) of several
progressive neurological disorders. The 14-3-3 protein is
o n es u p p o r t i v ea n de s s e n t i a lm a r k e ri nt h eC S Fo f
sporadic Creutzfeldt-Jakob disease (CJD) patients. Peri-
odic sharp wave complexes (PSWC) observed on an
electroencephalographic (EEG) recording and the
presence of 14-3-3 in CSF are both included in the diag-
nostic criteria for CJD as supplied by the World Health
Organization (WHO) [2]. The 14-3-3 protein is detected
by Western blot (WB) in many clinical laboratories;
however, conducting a WB assay to detect 14-3-3 is
time consuming and expensive because the WB method
consists of many steps and requires multiple investiga-
tors to discern the protein bands [3]. Thus, the develop-
ment of a standard 14-3-3 protein assay and a valid
criterion for quantitative assessment is urgently
required.
The 14-3-3 protein has been reported to be a detect-
able biomarker, especially in the CSF of CJD patients, by
WB or enzyme-linked immunosorbent assay (ELISA).
However, the WB to detect 14-3-3 is not very sensitive
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Previous studies have utilized an ELISA to detect 14-3-3
in the CSF [4,5] (Additional file 1, table S1), but four pro-
blems were encountered: the number of CJD patients was
less than 50; the make-up of the CJD and case-control
groups was not clear; the analytic means of the cut-off data
for the ELISA were unclear; and the specificity was very
low. We attempted to improve upon these four problems
and attempted to develop a new, specific, 14-3-3g ELISA.
We developed a specific ELISA using the gamma iso-
form of 14-3-3 (14-3-3g). Additionally, results from the
WB and ELISA analyses were compared. We analyzed 124
human prion disease cases and 99 human non-prion dis-
ease cases using the 14-3-3g ELISA and assessed if quanti-
fication of 14-3-3 might be helpful in their differentiation.
Methods
1. Patients
Patients with suspected CJD were recruited from hospitals
all over Japan for the purpose of conducting biochemical
CSF assays. From more than 300 requests, a follow-up
study was performed with 124 CJD patients. The cases
were classified as sporadic CJD (n = 114), genetic CJD (n =
7; four cases with a V180I mutation, two cases with an
M232R mutation and a single case with an E200K mutation
in the prion protein gene), or iatrogenic CJD (dura-asso-
ciated CJD; n = 3). A total of 114 sporadic CJD patients
and 3 iatrogenic CJD patients did not express a prion pro-
tein gene (PRNP) mutation. All 124 cases contained MM at
codon 129 and EE at codon 219 of the PRNP.
Subjects for the present study consisted of 114 spora-
dic CJD patients with confirmed CJD diagnosis. All 114
sporadic patients fulfilled the WHO diagnostic criteria
for CJD. All sporadic CJD cases were typical with
respect to clinical findings, clinical time course, neuroi-
maging [FLAIR and diffusion-weighted magnetic reso-
nance imaging (DWI-MRI) with high signal
abnormalities in the caudate nucleus and putamen, or at
least two cortical regions] and PSWCs via EEG.
A total of seven sporadic CJD cases (four males, three
females) were definite, and 107 sporadic cases were
probable among the 114 sporadic CJD patients. Two
cases (V180I; females) were definite cases among the
seven genetic CJD cases, and one case was a definite
among the three iatrogenic CJD cases.
For control samples, CSF was collected from 99 patients
who suffered from one of the following disorders: demen-
tia of Alzheimer’s type (DAT; n = 54, 33 male, 21 female),
cerebrovascular dementia (n = 7, 5 male, 2 female), Par-
kinson’s disease (n = 5, 4 male, 1 female), progressive
supranuclear palsy (PSP; n = 3, 2 male, 1 female), fronto-
temporal lobular degeneration (n = 2, 1 male, 1 female),
Huntington’s disease (n = 1; 1 male), corticobasal
degeneration (n = 2, both female), amyotrophic lateral
sclerosis (n = 3, 1 male, 2 female), limbic encephalitis (n =
2, 1 male, 1 female), mitochondrial myopathy, encephalo-
pathy, lactic acidosis and stroke-like episodes (MELAS; n
= 4, 2 male, 2 female), paraneoplastic cerebellar disorder/
Lambert-Eaton myasthenic syndrome (PCD/LEMS; n = 2,
1 male, 1 female), temporal epilepsy (n = 4, 1 male, 3
female), mild cognitive impairment (n = 3, 1 male, 2
female), and dementia etiology unknown (n = 3, 1 male, 2
female). Additionally, CSF was obtained from healthy
volunteers (n = 4, 2 male, 2 female).
All subjects were examined and CSF samples col-
lected, divided into aliquots, and stored at -80°C until
required. All assays were performed simultaneously to
avoid repeated freezing and thawing of samples. The
CSF samples were used within 1 month of collection.
We previously reported about 21 patients that suffered
from early-stage CJD, defined as cases in the 6 weeks fol-
lowing the onset of the disease [6]. We used the CSF sam-
ples and clinical findings of these 21 patients. This study
was approved by the Medical Ethics Committee of Naga-
saki University, School of Medicine (06012755;
UMIN000003301), and the participants provided written
informed consent.
2. Analysis of CSF by WB for 14-3-3
The CSF samples were collected, aliquoted, and stored
at -80°C until required. All assays were performed
simultaneously to avoid repeated freezing and thawing
of samples. Immunoassays for 14-3-3 protein were per-
formed as previously described [3]. Polyclonal antibodies
specific for 14-3-3g were obtained from Immuno-Biolo-
gical Laboratories (18647; Gunma, Japan) and were used
at a dilution of 1:500. Polyclonal antibodies specific for
all isoforms of 14-3-3 were obtained from Santa Cruz
Biotechnology (sc-1657; Santa Cruz, CA, USA) and used
at a dilution of 1:1, 000. All samples were analyzed
using the same antibody to ensure comparable sensitiv-
ities. Protein detection was performed using an
enhanced chemiluminescence detection kit (Amersham
Buchler Company). Detection of 14-3-3 in the CSF sam-
ples was performed as previously described [3]. All
assays were performed by two independent researchers.
3. Analysis of total tau protein in CSF samples
Detection of total tau protein in the CSF samples was
performed as previously described [6].
4. ELISA detection of 14-3-3 in CSF
We immunized rabbits and mice with eight 14-3-3g pep-
tides and obtained three monoclonal antibodies (clones
#4-#6; additional files 2, table S2) and three polyclonal
antibodies (clones #1-#3; additional file 2, table S2). These
six antibodies were characterized and the best
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determined (clones #1 and # 6; Additional file 3, figure
S1). The sandwich ELISA for detection of 14-3-3g was
used to analyze CSF samples from 124 CJD patients and
the remaining 99 patients with other diseases. The ELISA
assay was sensitive enough to detect 14-3-3g in the range
125-16, 000 AU/ml in human CSF samples. The ELISA
plates were coated with antibody and then 50 μlo fC S F
and 50 μl of sample dilution buffer was added to each
well. The samples were incubated for 1 hour at room tem-
perature. Following incubation in the appropriate second-
ary antibody, samples were reacted with horseradish
peroxidase and the optical density of each well at 450 nm
was determined using a microplate reader. All processes
were completed within a 4-hour period.
5. Analysis by the real-time QUIC (RT-QUIC) method
Analysis by the RT-QUIC method was performed as
previously described [7].
6. Statistical analysis
SPSS version 11.0 software was used to perform all sta-
tistical analyses. Standard measures of diagnostic test
validity were used to identify true-positive, true-negative,
false-positive, and false-negative results. The levels of
14-3-3g in the 124 CJD patients and remaining 99
patients with other diseases were used for these calcula-
tions [receiver operating characteristic (ROC) analysis].
7. MRI Protocol and PSWC on EEGs
We have described the MRI protocol and PSWC on
EEGs previously [6].
Results
1. Detection of 14-3-3 by WB in CSF samples
In the CJD group, 14-3-3 was detected in all CSF sam-
ples (n = 124; Tables 1 and 2). The 14-3-3 protein was
detected in two non-CJD patients with DAT, one with
CVD, two with Wernicke’s encephalopathy, and three
patients with limbic encephalitis. The WB sensitivity
and specificity for 14-3-3g in CJD patients was 87.1 and
84.8%, respectively (Tables 1 and 2, Figure 1-a, b, c). In
other hand, WB sensitivity and specificity for all iso-
forms of 14-3-3 in CJD patients was 91.4 and 78.8%
(Tables 1 and 2).
2. Detection of total tau protein in CSF Samples
The levels of total tau protein in CSF were determined
in 223 patients, and significant differences were
observed among individuals (Tables 1 and 2). The level
of total tau protein was highest in the CJD group, ran-
ging from 1, 048-146, 087 pg/ml (mean ± SD, 7, 174 ±
6, 558 pg/ml). The CJD patients expressed higher levels
of total tau proteins compared with patients suffering
from other neurological disorders patient (p <0 . 0 1 ;
Tables 1 and 2, Figure 1).
3. Detection of 14-3-3 in CSF samples by ELISA
The levels of 14-3-3 in CSF were determined in 223
patients, with significant differences observed among
individuals. The level of 14-3-3 was greatest in the CJD
group, ranging from 135-75, 373 AU/ml (mean ± SD,
263, 549 ± 21, 525 AU/ml; Table 2-a). In the DAT group,
the concentration of 14-3-3 was between 0-2, 410 AU/ml
(mean ± SD, 1, 537 ± 751.2 AU/ml). The CVD group
exhibited levels similar to those in the DAT group, with a
range of 521-1, 512 AU/ml (mean ± SD, 975.9 ± 332.4
AU/ml). The level of 14-3-3 in CJD patients was also
higher compared with patients suffering other neurologi-
cal disorders, including the CVD and DAT groups (p <
0.01). A cut-off (1, 683 AU/ml) was determined by an
ROC curve (Figure 1-a). The sensitivity and specificity
f o rd e t e c t i o no f1 4 - 3 - 3i nC J Dp a t i e n t sw a s9 5 . 2a n d
72.7%, respectively (Tables 1 and 2, Figure 1-a, b, c). We
were able to demonstrate that these ELISA results were
reproducible (additional file 4, figure S2-a, b)
4. Analysis of biochemical markers in 21 early-stage CJD
patients
We previously published a report outlining 21 subjects
that suffered from early-stage CJD, which was defined
as cases in the 6 weeks following the onset of disease
[6]. The sensitivities for detection of total tau protein
and 14-3-3 in CSF were analyzed to determine their
usefulness as diagnostic markers of early-stage CJD.
Total tau and 14-3-3 proteins were detected in 95.2
and 76.2%, respectively, of the early-stage CJD patients.
In all 21 patients, the data exceeded the cut-off data (>
1, 683 AU/ml) for the 14-3-3 ELISA (Table 3). Addi-
tionally, DWI-MRI was used to positively identify
90.5% of these cases. All cases were able to be diag-
nosed using a combination of DWI-MRI and 14-3-3g
ELISA.
5. Analysis of CJD patients where 14-3-3g was not
detected by WB yet the concentration of 14-3-3g
exceeded the ELISA cut-off level (Table 4)
In seven of the 124 CJD patients, 14-3-3g was not
detected by the WB but their values were above the cut-
off level (1, 683 AU/ml) as determined by the 14-3-3g
Table 1 The sensitivity and the specificity of ELISA of 14-
3-3 g protein, the detection of 14-3-3 g protein and 14-3-
3a protein in WB methods
14-3-3 g-isoform 14-3-3 all isoforms
ELISA WB WB
sensitivity (%) 95.2 87.1 91.4
specificity (%) 72.7 84.8 78.8
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with other neurological disorders and rapid progressive dementia
disease number male female 14-3-3 g 14-3-3 all isoforms
ELISA WB WB
average SD min max
CJD 124 69 55 263, 549 21, 525 135 75, 373 108/124 114/124
DAT 54 33 21 1, 537 751.2 0 2, 410 3/54 7/54
CVD 7 5 2 975.9 332.4 521 1, 51 2 0/7 2/7
PD 5 4 1 542.2 20.3 521 565 0/5 0/5
PSP 3 2 1 223.3 226.6 38 476 0/3 0/3
FTLD 2 1 1 425 236.2 258 592 0/2 0/2
HD 1 1 0 556 0. 556 556 0/1 0/1
CBD 2 2 0 449.5 245.4 276 623 0/2 0/2
ALS 3 1 2 303.7 184.8 179 516 0/3 0/3
limbic encephalitis 2 1 1 4440.5 1935.4 3, 072 5, 809 2/2 2/2
MELAS 4 2 2 5, 069.5 222.7 4, 912 5, 227 4/4 4/4
PCD/LEMS 2 1 1 4, 387 217.8 4, 233 4, 541 2/2 2/2
temporal epilepsy 4 1 3 3, 356.8 1332.4 1, 530 4, 696 4/4 4/4
MCI 3 1 2 603 20.8 591 627 0/3 0/3
Dementia, etiology unknown 3 1 2 410.3 150.5 258 559 0/3 0/3
healthy subject 4 2 2 0 0 0 0 0/4 0/4
CJD: Creutzfeldt-Jakob disease, DAT: Dementia of Alzheimer’s type, CVD: Cerebral Vascular Disorder, PD: Parkinson’s disease, PSP: progressive supranuclear palsy,
FTLD: frontotemporal lobular degeneration HD: Huntington’s disease, CBD: corticobasal degeneration, ALS: amyotrophic lateral sclerosis, MELAS: Mitochondrial
myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes, PCD: paraneoplastic cerebellar degeneration, LEMS: Lambert-Eaton myasthenic syndrome, MCI:
mild cognitive impairment,
Figure 1 ELISA analysis of 14-3-3 protein in CSF from patients with CJD and other neurological disorders. 1-a. Receiver operating curve
characteristics at different cut-off points for the 14-3-3 ELISA applied to CSF samples. 1-b. Results of the 14-3-3 ELISA analysis in CSF from
patients with CJD and other forms of dementia. CJD, Creutzfeldt-Jakob disease; DAT, dementia of Alzheimer’s type; CVD, cerebrovascular
disorders; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; FTLD, frontotemporal lobular degeneration; HD, Huntington’s disease; CBD,
corticobasal degeneration; PCD/LEMS, paraneoplastic cerebellar disorder/Lambert-Eaton myasthenic syndrome; MELAS, mitochondrial myopathy,
encephalopathy, lactic acidosis and stroke-like episodes; MCI, mild cognitive impairment. 1-c. Comparison of CJD patients and non-prion patients.
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five sporadic CJD patients were longer when compared
with the classical CJD patients.
6. Analysis of CJD patients where 14-3-3g was not
detected using WB and 14-3-3g concentration was below
the cut-off level for the ELISA (Table 5)
For seven of the 124 CJD subjects, 14-3-3g was not
detected using the WB method and the concentration
of the protein was below the cut-off level (1, 683 AU/
ml) as determined by the 14-3-3g ELISA (Table 5).
Five of the genetic CJD patients had the V180I muta-
tion, and the remainder had the M232R slow-type
mutation. The clinical courses of the disease in the five
genetic CJD patients were longer than for the classical
CJD patients.
7. Analysis of non-CJD patients with positive 14-3-3g
ELISA diagnoses (Table 6)
The results from 23/99 of the non-CJD patients demon-
s t r a t e dt h a tt h ec o n c e n t r a t i o no f1 4 - 3 - 3 g exceeded the
cut-off limit. When the concentration of 14-3-3g was
Table 3 Summary of the detection of ELISA of 14-3-3 protein, the detection of WB method of 14-3-3 protein and in
CSF for 21 patients with early-stage CJD





the detection of WB method of
14-3-3a protein





71 m sp probable 0 4, 157 - - + +
77 m sp probable 2 10, 812 + + + +
64 f sp probable 4 11, 812 + + + +
73 m sp probable 4 3, 850 + + - +
67 m sp probable 4 10, 814 + + + +
76 m sp probable 4 6, 772 + + + +
80 f sp probable 4 9, 850 + + + +
63 f sp probable 4 2, 987 - - - +
67 m sp probable 4 3, 553 + + + +
70 f sp probable 4 3, 729 - - - +
63 m sp probable 4 6, 133 + + + +
63 m sp probable 4 8, 297 + + + +
67 f sp probable 5 3, 372 + - - -
74 m sp probable 5 7, 184 + + + +
69 f sp definite 6 5, 600 + + + +
54 f sp definite 6 1, 897 - - - +
70 f ia probable 6 9, 460 + + + -
70 f fa probable 6 4, 417 + + + +
64 f sp probable 6 3, 888 + + + +
51 f ia probable 6 6, 313 + + + +
74 f sp probable 6 6, 133 + + + +
sp = Sporadic CJD; ia = iatrogenic CJD; fa = familiar CJD; d.l. = diagnostic level based on the WHO and the Masters criteria; d.w. = duration from the onset of the
disease to the diagnostic examination. In all 21 cases, codon 129 of PRNP was Met/Met homozygous, whereas codon 219 was Glu/Glu homozygous. Total protein
contents of all the patients stayed within the normal range. All patients in this study were Asian.
Table 4 Analysis of CJD patient s that were not detected in 14-3-3g protein of WB methods but were beyond the cut-
off level (1, 683 AU/ml) in 14-3-3 protein ELISA
Age Sex type Polymorphism








69 male sp MM - 2, 101 +
33 female sp MM - 1, 852 +
70 female sp MM - 2, 452 -
73 female sp MM - 2, 531 -
64 male sp MM - 5, 493 +
65 male fa MM E200K 4, 621 +
79 female sp VV - 2, 342 +
sp: sporadic type, ge: genetic type, MM: methioine homozygotes, VV: valine homozygotes, +: positive, -: negative
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could also be detected by WB. Patients diagnosed with
PCD/LEMS, MELAS, limbic encephalitis, temporal epi-
lepsy, and a part of DAT were pseudo-positive, but
negative using the RT-QUIC method.
Discussion
We attempted to develop a sandwich ELISA using com-
binations of the specific g-isoform antibodies (clones #1,
#2 and #6: additional file 2, table S2), but only one com-
bination of antibodies (#1 and #6: additional file 2, table
S2) showed a dose-dependent reaction (Additional files
3, figure S1-a). The #1 and #6 antibodies reacted with
the g-isoform of 14-3-3.
There are clear advantages for using an ELISA over a
WB for the detection of 14-3-3 in CSF samples. The
WB method requires many steps for the detection of
the target protein, with the WB protocol varying
between laboratories. Thus, it is very difficult to obtain
consistent data regarding the number, location and
intensity of banding patterns. Moreover, the WB
method can assay several samples simultaneously. It is
an unsuitable method for patients in urgent need of
treatment. However, the ELISA method allows for
simultaneous processing of numerous CSF samples and
appears to be the best method for use in a clinical
setting.
In this study, we developed a sensitive and precise
ELISA method for the quantification of 14-3-3 in CSF.
The ELISA analysis of CSF in CJD patients was stratified
by diagnosis category, and indicated a significantly
higher 14-3-3 level in definite as well as probable CJD
patients, compared to the CSF from patients with other
neurological disorders.
Additionally, seven cases were analyzed by ELISA as
the protein levels could not be determined by WB.
These seven cases were classified into two categories
(Tables 5 and 6). The first category consisted of samples
with a total tau protein concentration exceeding 1, 300
pg/ml, with the concentration of 14-3-3 greater than 1,
683 AU/ml as determined by the ELISA. The second
category consisted of samples with a total tau protein
concentration less than 1, 300 pg/ml, but 14-3-3 con-
centration greater than 1, 683 AU/ml according to the
ELISA (Table 5). All samples from CJD patients were
assayed using the WB method for detecting 14-3-3 and
the ELISA method for detecting total tau protein. This
is because four patients exhibited a positive reaction for
total tau (> 1, 300 pg/ml) and a negative reaction for
14-3-3 protein by WB; these four patients were also
positive using the 14-3-3 ELISA (Table 4 and 5). We
suggest that it might be unnecessary to check for both
14-3-3 and total tau proteins.
The present study varied from previous ELISA studies.
In previous studies, all isoforms of 14-3-3 were detected,
whereas in the present study we only detected the g-iso-
form. The amount of 14-3-3g was elevated in the CSF of
CJD patients, consistent with previous WB studies. In a
particular study [5], an ELISA method that measured all
isoforms of 14-3-3 proved to be very useful. However,
this system is not commercially available. Additionally,
data from the ELISA method cannot be compared to
previous results based on the b-o rg-isoform. However,
the method described in the present study allows for
these comparisons, with high specificity and sensitivity
compared to other studies [2]. The differences in sensi-
tivity and specificity for 14-3-3 diagnosis in various stu-
dies are likely due to the lack of uniformity between the
diseases, as well as the number of diseases associated
with 14-3-3. Previous studies [8,9] have shown that WB
sensitivity and specificity for 14-3-3 are useful for diag-
nosis. However, the ELISA method is standardized,
allowing for data comparison between subsequent stu-
dies. All ELISA procedures are completed within 4
hours, but the WB method requires 2-3 days. In addi-
tion, the ELISA assay can simultaneously analyze 40
samples from eight individuals.
Our previous report identified that the detection of
total tau protein combined with DWI-MRI identified
98% of the early-stage cases. Pennington C et al [10]
Table 5 Analysis of CJD patient s that were not detected in 14-3-3g protein of WB methods and were below the cut-
off level (1, 683 AU/ml) in 14-3-3 protein ELISA
Age Sex type Polymorphism








85 female ge MM V180I 1, 086 -
84 female ge MM V180I 1, 222 -
84 male ge MM V180I 1, 313 -
84 female ge MM V180I 1, 383 -
75 male ge MM M232R 1, 676 +
78 male sp MM - 135 -
66 male sp MM - 1, 224 +
sp: sporadic type, ge: genetic type, MM: methioine homozygotes, VV: valine homozygotes, +: positive, -: negative
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sensitive at the early stages of CJD, with CSF tau protein
having the greatest specificity and efficiency. However,
an ELISA to detect 14-3-3 was the most sensitive of the
biochemical markers from the same samples. These
findings indicate that a combination of DWI-MRI and
14-3-3g ELISA are the most effective tests for detecting
CSF protein markers during the early stages of CJD.
There were two problems with our study: 20 DAT
cases identified that the level of ELISA was 3, 000-5,
000 AU/ml, but they could not be detected by WB and
these results showed a discrepancy between the 14-3-3g
WB and ELISA (additional file 3, figure S1-a); and the
specificity of the ELISA was very low (Figure 1). In this
study we established an ELISA method for the detection
of 14-3-3g in CSF. The levels of 14-3-3 in the CSF of
CJD patients were significantly elevated compared with
those in other patients with neurological disorders. In
various studies, the differences in sensitivity and specifi-
city for detection of 14-3-3 were likely due to the lack
of uniformity between the diseases, as well as the num-
ber of diseases that are associated with 14-3-3. The
detection limit of the g-isoform by WB was equivalent
to 3, 400-4, 600 AU/ml by the ELISA, thus very low
levels of 14-3-3g in the CSF of DAT patients were con-
firmed using the ELISA (Table 6).
One of the reasons why the specificity was low was the
combination of monoclonal antibodies used in the sand-
wich ELISA. If we had developed the ELISA using a com-
bination of specific g-isoform antibodies, such as clone
#3, it is likely that the specificity may have been greater.
Atarashi et al. [7] detected the abnormal prion protein in
CSF using the RT-QUIC method, with the specificity of
the RT-QUIC method at 100%. These findings indicate
the promise of an enhanced diagnostic capacity of RT-
QUIC in the antemortem evaluation of suspected CJD.
The RT-QUIC method has high specificity and moderate
sensitivity in suspected CJD cases. Therefore, the cut-off
limit for ELISA assay sensitivity was close to 100% because
the specificity of the RT-QUIC method was 100%. Differ-
ential diagnosis is crucial, in particular because the num-
ber of false positive results may increase (Table 6).
Additionally, the subtype of false negative results with
human prion disease is also important (Tables 4 and 5).
Conclusion
We have established an ELISA that specifically detects
14-3-3g,a n dw eb e l i e v et h a to u rE L I S Ai sa n
Table 6 The summary of non-CJD patients in the positive cases of ELISA of 14-3-3 g protein
Age Sex diagnosis WB (14-3-3 protein) ELISA Real-time QUIC method
all isoforms g-specific isoform g-specific isoform
79 male PCD/LEMS + + 4, 233 -
69 male PCD/LEMS + + 4, 541 -
51 female temporal epilepsy + + 3, 405 -
59 female temporal epilepsy + + 3, 796 -
62 male limbic encephalitis + + 3, 072 -
78 male limbic encephalitis + + 5, 809 -
42 female MELAS + + 4, 912 -
25 female MELAS + + 5, 227 -
78 male DAT + + 3, 110 -
62 female DAT + + 3, 386 -
69 female DAT + + 3, 892 -
57 male DAT + - 3, 092 -
59 male DAT + - 3, 074 -
61 male DAT + - 3, 038 -
66 female DAT + - 2, 941 -
67 female DAT - - 2, 569 -
70 female DAT - - 2, 534 -
78 female DAT - - 2, 445 -
83 female DAT - - 2, 410 -
89 female DAT - - 2, 025 -
72 male DAT - - 1, 949 -
59 female DAT - - 1, 852 -
63 male DAT - - 1, 709 -
PCD: paraneoplastic cerebellar degeneration, LEMS: Lambert-Eaton myasthenic syndrome, MELAS: Mitochondrial myopathy, Encephalopathy, Lactic Acidosis,
Stroke-like episodes, DAT: Dementia of Alzheimer’s type
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prion diseases. We think that the combination of an
ELISA specific for 14-3-3g and the RT-QUIC method
are the best diagnostic tools that can be used to detect
human prion diseases in CSF.
Additional material
Additional file 1: Table S1. The profiles of all researches in the
sensitivity and specificity of ELISA kits of 14-3-3 protein in CJD
patients. ELISA: WB: Western blots method, N.E.: not exminated We
compared the previous reports of ELISA kits of 14-3-3 protein in CSF of
CJD patients with our data. Supplementary reference. 1. Geschwind MD,
Martindale J, Miller D et al. Challenging the clinical utility of the 14-3-3
protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Archives
of neurology. 2003;60:813-816. 2. Kenney K, Brechtel C, Takahashi H et al.
An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in
the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients.
Annals of Neurology. 2000; 48:395-398. 3. Gmitterova K, Heinemann U,
Bodemer M et al. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease
differ across molecular subtypes. Neurobiology of Aging. 2009; 30(11):
1842-50.
Additional file 2: Table S2. The characterization of three
monoclonal antibodies and three polyclonal antibodies in six
isoforms of 14-3-3 protein. 14-3-3 proteins are a highly conserved
family of multifunctional proteins which are primarily found in high
levels in neurons. These proteins comprise seven distinct isoforms (b-
isoform, g-isoform, h-isoform, ε–isoform, ζ-isoform, τ-isoform and s-
isoform), but s-isoform has not been detected in the human brain. We
analyzed six isoforms (b-isoform, g-isoform, h-isoform, ε–isoform, ζ-
isoform and τ-isoform) in human CSF. We obtained the full-length gene
encoding each isoform ((b-isoform, g-isoform, h-isoform, ε–isoform, ζ-
isoform and τ-isoform) of 14-3-3 protein from a cDNA library. Full-length
constructs encoding either the b-o rg-isoform of human 14-3-3 protein
in addition to a His-tag were cloned into pcDNA6/His vector, after which
the constructs were transfected into murine 293T cell lines and over-
expressed. All isoforms of protein were collected and purified three times
through an affinity chromatography column. We analyzed all isoforms of
recombinant protein of 14-3-3 protein reacted by three monoclonal
antibodies (#1-#3) and polyclonal antibodies (#4-#6). Two monoclonal
antibodies (#1 and #2) and one polyclonal antibody (#6) were specific by
only g-isoform of 14-3-3 protein. But one monoclonal antibody (#3) and
two polyclonal antibodies (#4 and #5) were reacted by other isoforms
including g-isoform of 14-3-3 protein.
Additional file 3: Figures S1a and S1b. The standard curves
obtained for the sandwich ELISA (clones #1 and #6). The standard
curves obtained for the sandwich ELISA (clones #1 and #6). The standard
control used a recombinant g-isoform of 14-3-3. The combination of
antibodies (#1 and #6) showed a dose-dependent reaction against the g-
isoform. Detection of 14-3-3 by the Western blot method in DAT
patients. Detection of 14-3-3 by the Western blot method in DAT
patients. Both cases 1 and 2 were DAT patients. The data from the 14-3-
3 ELISA indicated that the protein concentration in cases 1 and 2 were 3,
168 and 6, 773 AU/ml, respectively. The positive control (#3) was also
included.
Additional file 4: Figure S2a and S2b. The relationship between the
concentration of standard samples and the absorbance. The
relationship between the concentration of standard samples and the
absorbance. Correlation coefficient = 0.9967. The relationship between
the concentration of standard samples, and the absorbance in
different standard samples. The relationship between the
concentration of standard samples, and the absorbance in different
standard samples. These measurements were repeated five times. We
acquired the almost data similar to the fifth.
Acknowledgements
This study was supported by the members of Research Committee of Prion
disease and Slow Virus Infection from the Ministry of Health, Labour and
Welfare of Japan.
This study has no industry-sponsors.
The corresponding author is responsible for ensuring that all authors agree
with the Financial
Disclosure Statement.
Study funding and Funding disclaimer statement: This work was supported
by: the global COE Program (F12); a grant-in-aid for science research from
the Ministry of Education, Culture, Sports, Science and Technology of Japan;
a grant for BSE research; and Grants-in-Aid of the Research Committee of
Prion disease and Slow Virus Infection from the Ministry of Health, Labour
and Welfare of Japan.
Author details
1Department of Pharmaceutical Care and Health Sciences, Faculty of
Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Fukuoka 814-
0180, Japan.
2Department of Molecular Microbiology and Immunology,
Graduate School of Biomedical Science, Nagasaki University, 1-12-4
Sakamoto, Nagasaki 852-8523, Japan.
3Cyclex Co.LTD, 1063-103 Ohara,
Terasawaoka, Ina, Nagano 396-0002, Japan.
4Center for Community and
Campus Health, Nagasaki University, 1-14 Bunkyo, Nagasaki 852-8521, Japan.
5Nagasaki Kita Hospital, 800 Tokitsu, Nagasaki 851-2103, Japan.
Authors’ contributions
YM and KM: YM and KM performed the analysis of the 14-3-3γ ELISA, WB
and tau protein ELISA for human prion disease in CSF. TM: TM made the
development of a 14-3-3γ ELISA kit and the charge nurse of the sale
company of it SS: SS is a member of the CJD Surveillance Committee in
Japan from 2007 till 2011. RA: RA performed the analysis of the RT-QUIC
method for detecting human prion disease in CSF. AS and YK: investigators
in this study. KS: KS analyzed the 14-3-3γ ELISA, Western blots and tau
protein ELISA in CSF; KS is a member of the CJD Surveillance Committee in
Japan on 2012; and chief investigator of this study. NN:NN was the chief
manager of this study. All authors read and approved the final manuscript.
Competing interests
Yuki Matsui, Katsuya Satoh, Toshiaki Miyazaki, Susumu Shirabe, Ryuichiro
Atarashi, Kazuo Mutsukura, Yasufumi Kataoka and Noriyuki Nishida fulfill the
criteria for Conflicts of Interest (COI) as determined by the conflict of interest
committee of Nagasaki University and are protected by the “Policy of
Conflict of Interest in Clinical Research”.
All authors have no disclosures and no interest in the company, entity, or
organization.
Received: 22 April 2011 Accepted: 4 October 2011
Published: 4 October 2011
References
1. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG: The 14-3-3 brain
protein in cerebrospinal fluid as a marker for transmissible spongiform
encephalopathies. The New England journal of medicine 1996,
335(13):924-930.
2. Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A:
Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on
incidence estimates. Neurology 2000, 54(5):1095-1099.
3. Satoh K, Tobiume M, Matsui Y, Mutsukura K, Nishida N, Shiga Y, Eguhchi K,
Shirabe S, Sata T: Establishment of a standard 14-3-3 protein assay of
cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease.
Laboratory investigation; a journal of technical methods and pathology 2010,
90(11):1637-1644.3.
4. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr: An
enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the
cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients.
Annals of neurology 2000, 48(3):395-398.
5. Gmitterova K, Heinemann U, Bodemer M, Krasnianski A, Meissner B,
Kretzschmar HA, Zerr I: 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob
disease differ across molecular subtypes. Neurobiology of aging 2009,
30(11):1842-1850.
Matsui et al. BMC Neurology 2011, 11:120
http://www.biomedcentral.com/1471-2377/11/120
Page 8 of 96. Satoh K, Shirabe S, Tsujino A, Eguchi H, Motomura M, Honda H, Tomita I,
Satoh A, Tsujihata M, Matsuo H, et al: Total tau protein in cerebrospinal
fluid and diffusion-weighted MRI as an early diagnostic marker for
Creutzfeldt-Jakob disease. Dementia and geriatric cognitive disorders 2007,
24(3):207-212.
7. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T,
Nakagaki T, Yamanaka H, Shirabe S, et al: Ultrasensitive human prion
detection in cerebrospinal fluid by real-time quaking-induced
conversion. Nature medicine 2011, 17(2):175-178.
8. Chohan G, Pennington C, Mackenzie JM, Andrews M, Everington D, Will RG,
Knight RS, Green AJ: The role of cerebrospinal fluid 14-3-3 and other
proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the
UK: a 10-year review. Journal of neurology, neurosurgery and psychiatry
2010, 81(11):1243-1248.
9. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Saanchez-
Valle R, Mitrovaa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, et al: CSF tests
in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006,
67(4):637-643.
10. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R,
Green A: The role of cerebrospinal fluid proteins as early diagnostic
markers for sporadic Creutzfeldt-Jakob disease. Neuroscience letters 2009,
455(1):56-59.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/120/prepub
doi:10.1186/1471-2377-11-120
Cite this article as: Matsui et al.: High sensitivity of an ELISA kit for
detection of the gamma-isoform of 14-3-3 proteins: usefulness in
laboratory diagnosis of human prion disease. BMC Neurology 2011
11:120.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Matsui et al. BMC Neurology 2011, 11:120
http://www.biomedcentral.com/1471-2377/11/120
Page 9 of 9